Is radioiodine ablation with 1.1 GBq (30 mCi) I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
139 cases (median follow-up of 60 months).
I · Intervention 중재 / 시술
TT were recruited an divided in two groups according to RA (87 ablated and 87 non-ablated)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
No patient had evidence of structural disease at the end of follow-up. [CONCLUSIONS] Our findings support the recommendation against routine RA in low-risk DTC patients.
[BACKGROUND] In patients with low-risk differentiated thyroid cancer (DTC), remnant ablation with radioiodine (RA) after total thyroidectomy (TT) is controversial.
- 추적기간 60 months
APA
Ilera V, Califano I, et al. (2023). Is radioiodine ablation with 1.1 GBq (30 mCi) I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study.. Endocrine, 80(3), 606-611. https://doi.org/10.1007/s12020-023-03306-w
MLA
Ilera V, et al.. "Is radioiodine ablation with 1.1 GBq (30 mCi) I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study.." Endocrine, vol. 80, no. 3, 2023, pp. 606-611.
PMID
36988853 ↗
Abstract 한글 요약
[BACKGROUND] In patients with low-risk differentiated thyroid cancer (DTC), remnant ablation with radioiodine (RA) after total thyroidectomy (TT) is controversial. No benefits have been demonstrated in terms of mortality or disease-free survival. Recent evidence found that RA did not improve mid-term outcomes.
[PURPOSE] To evaluate initial response to treatment and long-term follow-up status in low-risk DTC patients after TT vs. TT + RA with I 1.11 GBq (30 mCi).
[METHODS] Prospective multicenter non-randomized study; 174 low-risk DTC that underwent TT were recruited an divided in two groups according to RA (87 ablated and 87 non-ablated). Response to treatment was evaluated at 6-18 months after thyroidectomy and at the end of follow-up with measurements of thyroglobulin, and anti-thyroglobulin antibodies levels, and neck ultrasonography.
[RESULTS] Baseline characteristics of both groups were similar. Ablated patients: median age 45.5 years, 84% females, 95.4% papillary thyroid carcinoma (PTC), mean tumor size 16 mm; non-ablated: median age 45 years, 88.5% females, 96.6% PTC, mean tumor size 14 mm. Response to initial treatment was similar between both groups, with < 2% of structural incomplete response. Final status was evaluated in 139 cases (median follow-up of 60 months). Among ablated patients, 82.8% had no evidence of disease (NED), 12% had an indeterminate response (IR) and 5% a biochemical incomplete response (BIR). Non-ablated patients had NED in 90%, IR in 8.7% and BIR in 1.2%. No statistical difference was found between groups (p = 0.29). No patient had evidence of structural disease at the end of follow-up.
[CONCLUSIONS] Our findings support the recommendation against routine RA in low-risk DTC patients.
[PURPOSE] To evaluate initial response to treatment and long-term follow-up status in low-risk DTC patients after TT vs. TT + RA with I 1.11 GBq (30 mCi).
[METHODS] Prospective multicenter non-randomized study; 174 low-risk DTC that underwent TT were recruited an divided in two groups according to RA (87 ablated and 87 non-ablated). Response to treatment was evaluated at 6-18 months after thyroidectomy and at the end of follow-up with measurements of thyroglobulin, and anti-thyroglobulin antibodies levels, and neck ultrasonography.
[RESULTS] Baseline characteristics of both groups were similar. Ablated patients: median age 45.5 years, 84% females, 95.4% papillary thyroid carcinoma (PTC), mean tumor size 16 mm; non-ablated: median age 45 years, 88.5% females, 96.6% PTC, mean tumor size 14 mm. Response to initial treatment was similar between both groups, with < 2% of structural incomplete response. Final status was evaluated in 139 cases (median follow-up of 60 months). Among ablated patients, 82.8% had no evidence of disease (NED), 12% had an indeterminate response (IR) and 5% a biochemical incomplete response (BIR). Non-ablated patients had NED in 90%, IR in 8.7% and BIR in 1.2%. No statistical difference was found between groups (p = 0.29). No patient had evidence of structural disease at the end of follow-up.
[CONCLUSIONS] Our findings support the recommendation against routine RA in low-risk DTC patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.